[A22-78] Pembrolizumab (small bowel cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 02.11.2022
Commission awarded on 21.07.2022 by the Federal Joint Committee (G-BA).
Adults with unresectable or metastatic microsatellite instability high or mismatch repair deficient small intestine cancer, who have disease progression on or following at least one prior therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.